Vaccines (Jul 2022)
Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
- Yuntao Zhang,
- Wenjie Tan,
- Zhiyong Lou,
- Yuxiu Zhao,
- Jin Zhang,
- Hongyang Liang,
- Na Li,
- Xiujuan Zhu,
- Ling Ding,
- Baoying Huang,
- Weimin Zhou,
- Yancen Guo,
- Zhaona Yang,
- Yuling Qiao,
- Zhenyu He,
- Bo Ma,
- Yao He,
- Di Zhu,
- Zhanhui Wang,
- Zhen Chang,
- Xue Zhao,
- Wei Wang,
- Ying Xu,
- Huiqin Zhu,
- Xiaotong Zheng,
- Chenlong Wang,
- Guangxue Xu,
- Guizhen Wu,
- Hui Wang,
- Xiaoming Yang
Affiliations
- Yuntao Zhang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Wenjie Tan
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
- Zhiyong Lou
- MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University, Beijing 100084, China
- Yuxiu Zhao
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Jin Zhang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Hongyang Liang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Na Li
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Xiujuan Zhu
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Ling Ding
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Baoying Huang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
- Weimin Zhou
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
- Yancen Guo
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Zhaona Yang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Yuling Qiao
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Zhenyu He
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Bo Ma
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Yao He
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Di Zhu
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Zhanhui Wang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Zhen Chang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Xue Zhao
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Wei Wang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Ying Xu
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Huiqin Zhu
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Xiaotong Zheng
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Chenlong Wang
- MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University, Beijing 100084, China
- Guangxue Xu
- MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University, Beijing 100084, China
- Guizhen Wu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
- Hui Wang
- Beijing Institute of Biological Products Company Limited, Beijing 100176, China
- Xiaoming Yang
- China National Biotec Group Company Limited, Beijing 100024, China
- DOI
- https://doi.org/10.3390/vaccines10071149
- Journal volume & issue
-
Vol. 10,
no. 7
p. 1149
Abstract
In response to the fast-waning immune response and the great threat of the Omicron variant of concern (VOC) to the public, we report the pilot-scale production of an inactivated Omicron vaccine candidate that induces high levels of neutralizing antibody titers to protect against the Omicron virus. Here, we demonstrate that the inactivated Omicron vaccine is safe and effective in recalling immune responses to the HB02, Omicron, and Delta viruses after one or two doses of BBIBP-CorV. In addition, the efficient productivity and good genetic stability of the manufactured inactivated vaccine is proved. These results support the further evaluation of the Omicron vaccine in a clinical trial.
Keywords
